Thousands of pharmacies that deliver medications directly to nursing-home residents now face a federal compliance requirement that could push many of them out of Medicare Part D networks. The Contract Year 2026 final rule, designated CMS-4208-F, requires every pharmacy in a Part D plan network to enroll in the Medicare Transaction Facilitator (MTF) Data Module and certify the accuracy of its enrollment data. Negotiated maximum fair prices for the first set of selected Part D drugs took effect January 1, 2026, and the MTF began operations at the same time. For large retail chains with dedicated regulatory teams, the new enrollment steps are manageable. For smaller, independent long-term care pharmacies that serve the bulk of nursing-home populations, the added administrative burden arrives without dedicated implementation funding and threatens to accelerate exits from plan networks.
How the MTF enrollment mandate pressures long-term care pharmacies
Long-term care pharmacies operate differently from corner drugstores. They package individualized medication regimens, coordinate with nursing staff on dosing schedules, and deliver supplies directly to facilities. These operations already run on thin margins, and the new rule adds a layer of data reporting that did not previously exist. Under the CY2026 final rule, pharmacy network agreements must require pharmacies to be enrolled in the MTF Data Module and to certify that their enrollment information is accurate and complete. The rule also includes a reduction in prescription drug event timeliness requirements for selected drugs, tightening the window in which pharmacies must submit claims data.
These requirements exist to support the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act of 2022. Through this program, CMS negotiates maximum fair prices with manufacturers for high-spend drugs covered under Part D, and those prices must be reflected consistently in plan payment and pharmacy reimbursement. The Government Accountability Office review of early implementation found that CMS designed the MTF process and manufacturer reimbursement timing to improve data flow between plans, manufacturers, and dispensing entities. That design, however, assumes pharmacies can absorb the compliance workload. Independent long-term care operators, which lack the back-office scale of national chains, face a steeper climb to meet the same technical and certification standards.
The MTF enrollment requirement is layered on top of existing accreditation, state licensing, and Part D network credentialing. Pharmacies must gather detailed ownership and practice information, align it with plan contracts, and maintain it over time as staff and corporate structures change. For multi-state long-term care operators, that means tracking variations in state rules while still meeting uniform federal data expectations. Any mismatch between MTF records, plan rosters, and claims submissions can trigger payment holds or retrospective audits, further straining cash flow for small operators already coping with lower reimbursement under negotiated prices.
Network exits could leave nursing homes without reliable drug supply
The real danger is not the paperwork itself but what happens when pharmacies that cannot keep up simply drop out of Part D networks. If independent long-term care pharmacies exit faster than retail chains, nursing homes in rural and underserved areas could lose their primary medication suppliers. Retail pharmacies rarely offer the specialized packaging, delivery logistics, and around-the-clock dispensing that institutional care demands. A nursing home that loses its long-term care pharmacy partner would need to find a replacement willing to serve an older, medically complex population at negotiated prices that are, by design, lower than previous reimbursement levels.
Part D plans are required to cover the first set of drugs selected under the negotiation program, according to CMS guidance on negotiated prices for the initial price applicability year. That coverage obligation means plans need pharmacies in their networks that can actually dispense those drugs to institutional patients. If the pharmacies most capable of handling complex regimens exit, plans may technically meet coverage rules on paper while residents encounter delays, partial fills, or fragmented sourcing from multiple retail outlets.
CMS has issued broader program guidance describing how negotiated prices, data reporting, and manufacturer payments are supposed to interact. The agency has also developed resources for dispensing entities that outline MTF enrollment steps, data elements, and timelines. Those materials may help sophisticated operators standardize their processes, but they do not change the underlying economics for small long-term care pharmacies that must invest in new systems and staff time without any direct offsetting revenue.
To prevent disruption in nursing-home medication access, policymakers and plans will need to watch for early warning signs: rising pharmacy terminations, longer delivery times, or increased use of emergency fills from retail outlets. Targeted technical assistance, streamlined data submission tools, or temporary flexibility on reporting timelines for very small providers could ease the transition without undermining the integrity of the negotiation program. Otherwise, the same policy that aims to make drugs more affordable for Medicare beneficiaries could unintentionally destabilize the fragile supply chain that keeps nursing-home residents safely medicated.
